Literature DB >> 22307472

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

Terri S Armstrong1, Patrick Y Wen, Mark R Gilbert, David Schiff.   

Abstract

Anti-angiogenic therapies, including bevacizumab, are being used with increasing frequency in the management of malignant glioma. Common clinically significant toxicities include hypertension and proteinuria, poor wound healing, and the potential for thromboembolic events. Literature related to the use of bevacizumab in malignant glioma, reported toxicities in this patient population, and management of these toxicities was reviewed. Recommendations for assessment and management are provided. Anti-angiogenic therapies will continue to have a role in the treatment of malignant glioma. Further studies of the prevention, assessment, and management of these toxicities are warranted.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22307472      PMCID： PMC3452334          DOI： 10.1093/neuonc/nor223

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  82 in total

1.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

Review 2.  Reversible posterior leukoencephalopathy syndrome in cancer.

Authors:  Christopher Vaughn; Louann Zhang; David Schiff
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

Review 3.  Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.

Authors:  Sanjaykumar Hapani; Amna Sher; David Chu; Shenhong Wu
Journal:  Oncology       Date:  2010-11-03       Impact factor: 2.935

Review 4.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

5.  AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

Authors:  O L Chinot; T de La Motte Rouge; N Moore; A Zeaiter; A Das; H Phillips; Z Modrusan; T Cloughesy
Journal:  Adv Ther       Date:  2011-03-14       Impact factor: 3.845

6.  Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Authors:  Emily S Robinson; Ursula A Matulonis; Percy Ivy; Suzanne T Berlin; Karin Tyburski; Richard T Penson; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 8.237

7.  Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Authors:  A Craig Lockhart; Mace L Rothenberg; Jakob Dupont; Wendy Cooper; Paul Chevalier; Lars Sternas; Giliane Buzenet; Elizabeth Koehler; Jeffrey A Sosman; Lawrence H Schwartz; David H Gultekin; Jason A Koutcher; Edwin F Donnelly; Ric Andal; Isabelle Dancy; David R Spriggs; William P Tew
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

8.  A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.

Authors:  Apurva A Desai; Nicholas J Vogelzang; Brian I Rini; Rafat Ansari; Stuart Krauss; Walter M Stadler
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

9.  Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy.

Authors:  Walter J Zawacki; T Gregory Walker; Emily DeVasher; Elkan F Halpern; Arthur C Waltman; Stephan T Wicky; David P Ryan; Sanjeeva P Kalva
Journal:  J Vasc Interv Radiol       Date:  2009-03-27       Impact factor: 3.464

10.  Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

Authors:  Mark A Socinski; Corey J Langer; Jane E Huang; Margaret M Kolb; Peter Compton; Lisa Wang; Wallace Akerley
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544
View more
  26 in total

Review 1.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

2.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

Review 3.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

4.  Primary brain tumors and posterior reversible encephalopathy syndrome.

Authors:  Carlos Kamiya-Matsuoka; David Cachia; Adriana Olar; Terri S Armstrong; Mark R Gilbert
Journal:  Neurooncol Pract       Date:  2014-09-14

5.  Wound healing complications in brain tumor patients on Bevacizumab.

Authors:  Harshad Ladha; Tushar Pawar; Mark R Gilbert; Jacob Mandel; Barbara O-Brien; Charles Conrad; Margaret Fields; Teresa Hanna; Carolyn Loch; Terri S Armstrong
Journal:  J Neurooncol       Date:  2015-08-23       Impact factor: 4.130

Review 6.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 7.  Antiangiogenic therapy of brain tumors: the role of bevacizumab.

Authors:  Elisa Trevisan; Luca Bertero; Chiara Bosa; Michela Magistrello; Alessia Pellerino; Roberta Rudà; Riccardo Soffietti
Journal:  Neurol Sci       Date:  2014-01-18       Impact factor: 3.307

8.  Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain.

Authors:  Jalal B Andre; Seema Nagpal; Daniel S Hippe; Ali C Ravanpay; Heiko Schmiedeskamp; Roland Bammer; Gerald J Palagallo; Lawrence Recht; Greg Zaharchuk
Journal:  Neuroradiol J       Date:  2015-04-28

9.  Anti-angiogenic therapy in high-grade glioma (treatment and toxicity).

Authors:  Jennie Taylor; Elizabeth R Gerstner
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

Review 10.  Safety of bevacizumab in patients with malignant gliomas: a systematic review.

Authors:  G Simonetti; E Trevisan; A Silvani; P Gaviani; A Botturi; E Lamperti; D Beecher; L Bertero; C Bosa; A Salmaggi
Journal:  Neurol Sci       Date:  2013-11-27       Impact factor: 3.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.